Itabmed

Developer of immunotherapeutics to treat cancer

placePudong, Shanghai, China calendar_todayFounded 2020 language itabmed.com

Innovation

3 patent families (1 granted) — focus: Chemistry & metallurgy; filing pace steady. Cited 1 times.

YearFilings
20211
20231
20251
20261

Investor mix

3 investors on record; lead investors include 3E BioVentures, Yongjin Group.

Investor typeCountShare
Venture capital133%
Private equity133%
Other / undisclosed133%
Coming soon